iiinova — where your digital self keeps evolving

@annaminchom.bsky.social on newer small cell therapeutic strategies and management of CRS and ICANS as specific TRAEs With thought around timings of dose delivery and education of AOS teams and patients, safely deliverable within the NHS #BTOG25

187

Tom Newsom-Davis @tnewsomdavis.bsky.social · 05/03/2025

With the successful role out of the TLHC programme, we now have a growing cohort of stage 1 SCLC patients. Hopefully this will become even more common, and work needed to understand optimal patient management @drjnaidoo.bsky.social #BTOG25

0134

Reposted by Jo Evans.

Graham Warren on smoking cessation in lung cancer pts. Extraordinary data: 🔺 $3.4bn cost of failed treatment if don’t quit 🔺 ⬇️ 45% mortality if quit 🔺Less frequent reminders more effective than more 🔺 Incredible ⬆️ survival if quit <6m after diagnosis: approx 4yr mOS benefit Sensational talk 🤯

097

Small cell in never smokers. On the rise for unknow reasons and a different biology. Having recently encountered my first patient who’s a never smoker(and no alcohol or recreational drugs), with extensive stage disease this insight is fascinating @stephenvliu.bsky.social #BTOG25

2276

@drjnaidoo.bsky.social on the limited stage small cell space and the excitement around CCRT-Durvalumab. EAMS currently open in England… #BTOG25

0105

DrLJ @drlaurajane.bsky.social · 04/03/2025

@stephenvliu.bsky.social on excitement in the Small Cell arena. PDL1/PD1 inhibition a practice changer, but so many potential game changers on the horizon from BITES To ADC, it’s exciting to see new drugs for an area of unmet need #BTOG25

0145

Reposted by Jo Evans.

“We’re talking about people’s lives, not just pathways. If it was your life on the line you wouldn’t settle for 64 days of waiting.” Patient perspective on waits for genomic testing in #lungcancer at #BTOG25

064

Reposted by Jo Evans.

Yvonne Diaz @yvonnediaz.bsky.social · 04/03/2025

Speed to diagnosis is key for ppl w #lungcancer- many of us are diagnosed at stage 4 when unwell. Great talk from Sandi Deans @nhsenglandldn.bsky.social Genomics at #BTOG25, illustrating the ideal pathway to reach the 14-day turnaround target in UK. Good to see ctDNA here #LCSM @btog.bsky.social

095

Magda Meissner on the Welsh ctDNA experience - an ‘in house’ solution assay wise and a huge amount of effort in validating and also learning to get more patients to test and more clinicians to genomic literacy #BTOG25

021

Debra Montague on ensuring the patient voice is not lost. The most important person in the room after all! We haven’t lost the patient voice but we all need to be better at listening! #BTOG25

1154

Tom Newsom-Davis @tnewsomdavis.bsky.social · 03/03/2025

Matthew Krebs on ctDNA and moving away from confirmatory tissue testing where an informative result is present. Key number 1% VAF for determining of non-actionable mutations are informative #BTOG25

031

Reposted by Jo Evans.

High pan-immune inflammation calue (PIV) associated with poor outcome me in ALK+ve disease @oncolojo.bsky.social

031

Caught the most amazing sunrise en route to the #BTOG25 5km… there are some benefits to wandering the streets at 6:30am 🤣

2151

BTOG @btog.bsky.social · 03/03/2025

Sandi Deans in delivering a 14 day genomics service, and the impact of the ctDNA pilots and roll out in potential time saving. CtDNA now pending addition to the Directory @BTOG25

0103

Reposted by Jo Evans.

Big news from #BTOG25 … next year’s event will be held in the beautiful city of Edinburgh 4-6 March 2026.

0105

Reposted by Jo Evans.

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 03/03/2025

We’re sharing patient insights on ALK+ #lungcancer trtmt at #BTOG25. Alectinib had the most side effects, Brigatinib the least. 30-45% on Lorlatinib reported visual, cognitive, or mood effects. When considering side effects alone, 71% chose Lorlatinib over Alectinib. Real experiences matter. #LCSM

0124

NLCA 2023. Captures genomics info for the first time. This is going to be crucial moving forwards #BTOG25

060

In 2018, with Tom Newsom-Davis, I wrote a chapter on novel immune check point targets for the ACP book ‘Problem Solving In Cancer Immunotherapy’. It’s fab to sit here and know my research wasn’t too far off and these targets now have drugs! Shobhit Baijal on ‘beyond PDL1/PD1 #BTOG25

072

Nicola Steele on the radical EGFRm arena - ADAURA-NEOADAURA-LAURA and a cheeky bit of PACIFIC. Targeted treatment sees gains across the board, and given PACIFIC data, LAURA a key trail. Needs desecration criteria to aid reimbursement? #BTOG25

031

Jan von der Thusen on the challenge of ADC biomarkers Biological validity: expression levels. What about tumoural heterogeneity? The impact of initial therapy on target antigen levels? #BTOG25

131

Prof Samreen Ahmed on ADCs and why they fail (or succeed - the utility of bystander functionality interesting) #BTOG25

131

DATO-DXd in EGFR interesting. 44% response rate in the pretreated group #BTOG25

012

Patrick Forde on ADCs - starting with TROP2 directed drugs - disappointing in the later line arena, against Docetaxel. A trend towards but not significant statistically. #BTOG25

011

The HER2 TKIs - EGFR TKIs not especially efficacious. First more selective HER2 TKIs - similar with high risk of grade 3 toxicity, aligned with what we saw with 1G and 2G EGFR TKIs. Zongertinib looking interest g from a response and TRAE point #BTOG25

021

Meenali Chitnis on HER2 as a target in lung cancer. We still have far to go in the uk… #BTOG25

121

Please do check out Roxane Chen’s (my iBSc student - a medical student) poster on pan-immune inflammation scoring and outcomes in ALK positive lung cancer. She worked so hard, and has been rewarded with the first abstract in the book, so no excuses not to engage, people! ❤️ No 1!! 🏅 #BTOG25

282